News

Cerillo Unveils Co-Culture Duet System for Real-Time Observation of Microbial Interaction Studies

Cerillo, a biotechnology company at the forefront of developing advanced research platforms for the study of the microbiome, hosted demonstrations of the company’s new co-culture duet system at ASM Microbe 2023.

Cerillo’s co-culture system will enable researchers to observe and study individual microbial populations in real time and measure the growth of one microbial population alongside other populations. The system’s porous barrier can physically isolate populations while maintaining fluidic contact, allowing researchers to mimic natural microbiome conditions and study the interactions between microorganisms.

The co-culture system is also scalable since it can be read in multiple microplate readers, each wirelessly connected to the company’s analytic software. This wireless feature can also help researchers capture and analyze growth data as it happens, enabling them to monitor and adjust their experiments in real time.

Until now, researchers faced the constraints of limited off-the-shelf co-culture options, demanding substantial investments of time and resources in developing custom systems for their studies. “Cerillo is dedicated to liberating microbiome researchers from the constraints of conventional laboratory technologies,” says Eric Mayton, CEO of Cerillo. “Our new co-culture system is a game-changer since it is the world’s first scalable, user-friendly, and cost-effective co-culture system.”

Applications

Cerillo’s co-culture system enables researchers to:

  • Mimic natural conditions: Microorganisms in the environment often exist in complex communities, where they interact with each other. Cerillo’s co-culture system allows researchers to mimic these natural conditions and study the interactions between microorganisms.
  • Improve understanding of microbial interactions: Cerillo’s co-culture system can provide insight into how microorganisms interact with each other. For example, one microorganism may produce a compound that benefits another microorganism, or one microorganism may inhibit the growth of another. These interactions can be difficult to study in isolation.
  • Identify novel compounds: Our system can also be used to identify novel compounds that are produced by microorganisms. For example, one microorganism may produce a compound that is only active in the presence of another microorganism.
  • Develop new therapies: Cerillo’s co-culture system can be used to screen for potential therapeutics by testing the ability of a compound to inhibit the growth of a pathogenic microorganism in the presence of a beneficial microorganism.

Features and Benefits

  • multiplexed plate accommodates 18 duets
  • physically accessible wells enable population sampling during and after experiments
  • compatible with other automation systems, giving you the freedom and flexibility to run additional assays on different platforms
  • effective for quick proofs-of-concept, and also preconfigured for higher-throughput work, making it suitable for a wide range of experiment types
  • scalable, enabling high-throughput experiments for faster results and comprehensive data analysis
  • small and robust to harsh conditions of incubators and anaerobic chambers
  • easily access your data without physical contact with your plate reader and manual memory cards

Learn more.

Recent News

12/19/2024

Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces FDA clearance to initiate a new additional Netherton Syndrome (NS) clinical study for QRX003. QRX003 is a topical lotion that contains a broad-spectrum serine protease inhibitor designed to target the kallikreins in

12/11/2024

Liquet™ Medical Inc. Receives FDA 510(k) Clearance for the Versus™ Catheter

Liquet Medical Inc., a pioneering medical device company committed to advancing patient care through innovative technologies, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Versus™ Catheter. This innovative medical device is set to enhance the treatment of pulmonary artery blood clots by offering real-time pulmonary artery

12/03/2024

ivWatch Named to Inc.’s 2024 Best in Business List in Health Products Category

ivWatch, LLC, the IV safety company, is proud to announce it has been named to the Inc. 2024 Best in Business list in the Health Products category. Inc.’s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made a profound impact on their industries and on society at large.